Morgensztern, D., Cobo, M., Ponce Aix, S., Postmus, P., Lewanski, C., Bennouna, J., . . . Investigators, O. B. O. T. A. L. (2018). ABOUND.2L+: A randomized phase 2 study of nanoparticle albumin‐bound paclitaxel with or without CC‐486 as second‐line treatment for advanced nonsquamous non‐small cell lung cancer (NSCLC). Wiley.
توثيق أسلوب شيكاغو (الطبعة السابعة عشر)Morgensztern, D., et al. ABOUND.2L+: A Randomized Phase 2 Study of Nanoparticle Albumin‐bound Paclitaxel with or Without CC‐486 as Second‐line Treatment for Advanced Nonsquamous Non‐small Cell Lung Cancer (NSCLC). Wiley, 2018.
توثيق جمعية اللغة المعاصرة MLA (الإصدار التاسع)Morgensztern, D., et al. ABOUND.2L+: A Randomized Phase 2 Study of Nanoparticle Albumin‐bound Paclitaxel with or Without CC‐486 as Second‐line Treatment for Advanced Nonsquamous Non‐small Cell Lung Cancer (NSCLC). Wiley, 2018.